Previous close | 48.45 |
Open | 48.45 |
Bid | 60.00 |
Ask | 63.95 |
Strike | 65.00 |
Expiry date | 2025-01-17 |
Day's range | 48.45 - 48.45 |
Contract range | N/A |
Volume | |
Open interest | 14 |
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursday. Thursday, Summit Therapeutics Inc (NASDAQ:SMMT) announced that Phase 3 HARMONi-2, or AK112-303, met its primary endpoint of progression-free survival (PFS). HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expre
** Prolific oil and gas developer Double Eagle is exploring a sale of its latest Permian Basin-based producer in a deal that could be worth more than $6.5 billion, including debt, according to people familiar with the matter. ** The owner of Britain's Royal Mail has agreed to a 3.57 billion pound ($4.55 billion) takeover by Czech billionaire Daniel Kretinsky, in a take-private deal of one of the world's oldest postal firms.